Answers are grounded in this paper and cite their sources.
Factor IX concentrates have been widely advocated in the treatment of haemophilic patients with factor VIII inhibitors. Five such patients were given the 'activated' factor IX concentrate--factor VIII inhibitor bypassing activity (Feiba)--for 14 separate bleeding episodes. In six of the episodes, including two with external blood loss, bleeding progressed in spite of treatment. In none of the other eight episodes was there a prompt response, and it was not possible to ascribe a definite therapeutic effect.
No takes yet. Share an insight, caveat, or question.
Parry et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: